Overcoming Early Phase Challenges in Alzheimer's Studies

April 29, 2012
Dr. Larry Ereshefsky, Vice President, Principal Pharmacologist, and Global Psychiatric Therapeutic Leader, of PAREXEL®, discusses our goals to diagnose and treat ahead of significant brain and neurological damage. Discover how to open the door for disease course modifying drugs, including primary and secondary prevention strategies.
Previous Video
Josh Schultz, Corporate VP Strategic Partnerships, recorded at Partnerships in Clinical Trials
Josh Schultz, Corporate VP Strategic Partnerships, recorded at Partnerships in Clinical Trials

Josh Schultz of PAREXEL discusses: What biopharmaceutical companies are looking for, major benefits and cor...

Next Video
Video of Dr. Goldberg, recorded at Partnerships in Clinical Trials
Video of Dr. Goldberg, recorded at Partnerships in Clinical Trials

Mark A. Goldberg, M.D., Chief Operating Officer of PAREXEL, discusses marketplace pressures and how clinica...